BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

244 related articles for article (PubMed ID: 25460507)

  • 1. Synthetic Aβ peptides acquire prion-like properties in the brain.
    Xiao X; Cali I; Yuan J; Cracco L; Curtiss P; Zeng L; Abouelsaad M; Gazgalis D; Wang GX; Kong Q; Fujioka H; Puoti G; Zou WQ
    Oncotarget; 2015 Jan; 6(2):642-50. PubMed ID: 25460507
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Distinct synthetic Aβ prion strains producing different amyloid deposits in bigenic mice.
    Stöhr J; Condello C; Watts JC; Bloch L; Oehler A; Nick M; DeArmond SJ; Giles K; DeGrado WF; Prusiner SB
    Proc Natl Acad Sci U S A; 2014 Jul; 111(28):10329-34. PubMed ID: 24982137
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Aβ43 aggregates exhibit enhanced prion-like seeding activity in mice.
    Ruiz-Riquelme A; Mao A; Barghash MM; Lau HHC; Stuart E; Kovacs GG; Nilsson KPR; Fraser PE; Schmitt-Ulms G; Watts JC
    Acta Neuropathol Commun; 2021 May; 9(1):83. PubMed ID: 33971978
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Age-dependent changes in brain, CSF, and plasma amyloid (beta) protein in the Tg2576 transgenic mouse model of Alzheimer's disease.
    Kawarabayashi T; Younkin LH; Saido TC; Shoji M; Ashe KH; Younkin SG
    J Neurosci; 2001 Jan; 21(2):372-81. PubMed ID: 11160418
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prion-like propagation of β-amyloid aggregates in the absence of APP overexpression.
    Ruiz-Riquelme A; Lau HHC; Stuart E; Goczi AN; Wang Z; Schmitt-Ulms G; Watts JC
    Acta Neuropathol Commun; 2018 Apr; 6(1):26. PubMed ID: 29615128
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Diversity in Aβ deposit morphology and secondary proteome insolubility across models of Alzheimer-type amyloidosis.
    Xu G; Fromholt SE; Chakrabarty P; Zhu F; Liu X; Pace MC; Koh J; Golde TE; Levites Y; Lewis J; Borchelt DR
    Acta Neuropathol Commun; 2020 Apr; 8(1):43. PubMed ID: 32252825
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Amyloid-beta42 interacts mainly with insoluble prion protein in the Alzheimer brain.
    Zou WQ; Xiao X; Yuan J; Puoti G; Fujioka H; Wang X; Richardson S; Zhou X; Zou R; Li S; Zhu X; McGeer PL; McGeehan J; Kneale G; Rincon-Limas DE; Fernandez-Funez P; Lee HG; Smith MA; Petersen RB; Guo JP
    J Biol Chem; 2011 Apr; 286(17):15095-105. PubMed ID: 21393248
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Aβ and tau prion-like activities decline with longevity in the Alzheimer's disease human brain.
    Aoyagi A; Condello C; Stöhr J; Yue W; Rivera BM; Lee JC; Woerman AL; Halliday G; van Duinen S; Ingelsson M; Lannfelt L; Graff C; Bird TD; Keene CD; Seeley WW; DeGrado WF; Prusiner SB
    Sci Transl Med; 2019 May; 11(490):. PubMed ID: 31043574
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Aß40 displays amyloidogenic properties in the non-transgenic mouse brain but does not exacerbate Aß42 toxicity in Drosophila.
    De Mena L; Smith MA; Martin J; Dunton KL; Ceballos-Diaz C; Jansen-West KR; Cruz PE; Dillon KD; Rincon-Limas DE; Golde TE; Moore BD; Levites Y
    Alzheimers Res Ther; 2020 Oct; 12(1):132. PubMed ID: 33069251
    [TBL] [Abstract][Full Text] [Related]  

  • 10.
    Jean L; Brimijoin S; Vaux DJ
    J Biol Chem; 2019 Apr; 294(16):6253-6272. PubMed ID: 30787102
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Aβ-induced acceleration of Alzheimer-related τ-pathology spreading and its association with prion protein.
    Gomes LA; Hipp SA; Rijal Upadhaya A; Balakrishnan K; Ospitalieri S; Koper MJ; Largo-Barrientos P; Uytterhoeven V; Reichwald J; Rabe S; Vandenberghe R; von Arnim CAF; Tousseyn T; Feederle R; Giudici C; Willem M; Staufenbiel M; Thal DR
    Acta Neuropathol; 2019 Dec; 138(6):913-941. PubMed ID: 31414210
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The interaction of insoluble Amyloid-β with soluble Amyloid-β dimers decreases Amyloid-β plaque numbers.
    van Gerresheim EF; Herring A; Gremer L; Müller-Schiffmann A; Keyvani K; Korth C
    Neuropathol Appl Neurobiol; 2021 Aug; 47(5):603-610. PubMed ID: 33338256
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prion-like behaviour and tau-dependent cytotoxicity of pyroglutamylated amyloid-β.
    Nussbaum JM; Schilling S; Cynis H; Silva A; Swanson E; Wangsanut T; Tayler K; Wiltgen B; Hatami A; Rönicke R; Reymann K; Hutter-Paier B; Alexandru A; Jagla W; Graubner S; Glabe CG; Demuth HU; Bloom GS
    Nature; 2012 May; 485(7400):651-5. PubMed ID: 22660329
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Human amyloid-β enriched extracts: evaluation of in vitro and in vivo internalization and molecular characterization.
    Pedrero-Prieto CM; Flores-Cuadrado A; Saiz-Sánchez D; Úbeda-Bañón I; Frontiñán-Rubio J; Alcaín FJ; Mateos-Hernández L; de la Fuente J; Durán-Prado M; Villar M; Martínez-Marcos A; Peinado JR
    Alzheimers Res Ther; 2019 Jun; 11(1):56. PubMed ID: 31253170
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prion protein is decreased in Alzheimer's brain and inversely correlates with BACE1 activity, amyloid-β levels and Braak stage.
    Whitehouse IJ; Miners JS; Glennon EB; Kehoe PG; Love S; Kellett KA; Hooper NM
    PLoS One; 2013; 8(4):e59554. PubMed ID: 23577068
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Large aggregates are the major soluble Aβ species in AD brain fractionated with density gradient ultracentrifugation.
    Sehlin D; Englund H; Simu B; Karlsson M; Ingelsson M; Nikolajeff F; Lannfelt L; Pettersson FE
    PLoS One; 2012; 7(2):e32014. PubMed ID: 22355408
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Rho-associated protein kinase 1 (ROCK1) is increased in Alzheimer's disease and ROCK1 depletion reduces amyloid-β levels in brain.
    Henderson BW; Gentry EG; Rush T; Troncoso JC; Thambisetty M; Montine TJ; Herskowitz JH
    J Neurochem; 2016 Aug; 138(4):525-31. PubMed ID: 27246255
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparative pathobiology of β-amyloid and the unique susceptibility of humans to Alzheimer's disease.
    Rosen RF; Tomidokoro Y; Farberg AS; Dooyema J; Ciliax B; Preuss TM; Neubert TA; Ghiso JA; LeVine H; Walker LC
    Neurobiol Aging; 2016 Aug; 44():185-196. PubMed ID: 27318146
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Differential changes in Aβ42 and Aβ40 with age.
    Miners JS; Jones R; Love S
    J Alzheimers Dis; 2014; 40(3):727-35. PubMed ID: 24503618
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Soluble amyloid beta peptide concentration as a predictor of synaptic change in Alzheimer's disease.
    Lue LF; Kuo YM; Roher AE; Brachova L; Shen Y; Sue L; Beach T; Kurth JH; Rydel RE; Rogers J
    Am J Pathol; 1999 Sep; 155(3):853-62. PubMed ID: 10487842
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.